Healthcare Industry News: Rad-8
News Release - August 11, 2009
Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) SystemJoint Development of a Two-way Interface Enabling Wired and Wireless Communication Now Underway
IRVINE, Calif. and JERUSALEM, Aug. 11 (Healthcare Sales & Marketing Network) -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, and Oridion (SIX Swiss Exchange: ORIDN), a global innovator of capnography monitoring solutions, today jointly announced an agreement to establish compatibility and connectivity between Oridion Capnostream(TM)20 portable bedside monitors and the Masimo Patient SafetyNet(TM) remote monitoring and clinician notification system. The agreement provides for joint development of a two-way interface allowing Patient SafetyNet to retrieve, analyze, and display physiological data from Capnostream monitors, while managing bi-directional communication and alarm features to facilitate earlier recognition of and clinical response to adverse respiratory events that require immediate clinical intervention.
According to a recently released HealthGrades study on patient safety in American hospitals, failure to rescue--which is defined as death occurring when an adverse clinical event is not recognized in time to save a patient with serious treatable complications--is the most common and most serious medical error at U.S. hospitals.(1) Masimo Patient SafetyNet was specifically developed to provide a new level of safety to patients on general care floors, where nurse-to-patient ratios can often preclude the level of direct surveillance required and recommended to preempt adverse events.
The key to a successful patient rescue is getting the right information to the right clinician at the right time. This means that accurate, reliable, and actionable patient data is necessary for rapid response or patient safety solutions to be effective. Oridion Capnostream monitors feature two industry-leading technologies--Oridion's patented Microstream(R) sidestream Smart Capnography(TM), and Masimo SET(R) Measure-Through Motion and Low-Perfusion pulse oximetry--that together provide clinicians with an early warning of a possible life-threatening deterioration in their patients' physiological status.
Oridion Microstream technology enables the most accurate and reliable assessment of breathing quality for patients requiring continuous ventilation monitoring, providing clinicians with timely recognition of changes that may lead to a decline in respiratory status or airway compromise. Masimo SET is the most accurate and reliable pulse oximetry technology, clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. Masimo Patient SafetyNet will be the first remote monitoring and clinician notification system to feature Oridion's newest Smart Capnography(TM) algorithm--Integrated Pulmonary Index(TM) (IPI)--enabling real-time tracking and trending of EtCO2, respiration rate, pulse rate, and SpO2 for an inclusive assessment of the patient's ventilatory status with a single index parameter.
According to Gerry Feldman, President of Oridion Systems Ltd., a partnership between the gold standards technologies in capnography and pulse oximetry "represents a winning combination for patients, clinicians and hospitals alike because a change in breathing quality and oxygenation can be important early indications that a patient may be heading for big trouble. The ability to quickly route this vital information to a qualified caregiver or rapid response team for appropriate clinical intervention can mean the difference between a timely rescue and failure to rescue. Oridion Microstream and Masimo SET technologies, together with the Masimo Patient SafetyNet system, will arm hospitals with the accurate, real-time information they need to make the most of their patient safety efforts."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are happy to partner with Oridion to expand the variety of vital sign parameters and third-party multi-parameter patient monitoring devices that offer real-time wireless connectivity to the Masimo Patient SafteyNet remote monitoring and clinician notification system. The Oridion Capnostream 20 monitor combines proven best-in-class measurements for oxygenation and ventilation in a portable and easy-to-use device for clinicians and patients in both hospital and outpatient settings. Enabling full connectivity and two-way wireless communication between Oridion Capnostream monitors and Masimo's Patient SafetyNet system will provide additional flexibility and monitoring options for healthcare facilities looking to advance patient safety and improve clinical outcomes."
Development of the two-way interface enabling full connectivity between Oridion monitors and Patient SafetyNet is now underway, with completion expected in Q4 of this year. Furthermore, existing Oridion Capnostream 20 monitors and Masimo Patient SafteyNet systems can be easily upgraded via software to add this functionality following full commercial release of the bi-directional interface.
Oridion Systems Ltd. (www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel. Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk. Additional information about Oridion and its products may be found at www.oridion.com.
Masimo (NASDAQ: MASI ) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the timing and availability of connectivity and a two-way interface between Oridion Capnostream and Masimo Patient SafetyNet, risks related to our belief that Patient SafetyNet will provide an effective early warning system to enable timely rescue, risks related to our belief that Masimo SET will provide sufficient sensitivity and specificity to detect physiological abnormalities and potentially life-threatening conditions in real-time for all patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation. Capnostream and Microstream are trademarks or registered trademarks of Oridion.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.